

Switching on Cytotoxicity of Water-Soluble Diiron Organometallics by UV Irradiation

Lorenzo Biancalana,* Manja Kubeil, Silvia Schoch, Stefano Zacchini, and Fabio Marchetti

Cite This: *Inorg. Chem.* 2022, 61, 7897–7909

Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: The diiron compounds $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CSEt})]\text{CF}_3\text{SO}_3$, **[1]** CF_3SO_3 , $\text{K}[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNCH}_2\text{CO}_2)]$, **K[2]**, $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CNMe}_2)]\text{NO}_3$, **[3]** NO_3 , $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\text{PTA})\{\mu\text{-CNMe}(\text{Xyl})\}]\text{CF}_3\text{SO}_3$, **[4]** CF_3SO_3 , and $[\text{Fe}_2\text{Cp}_2(\text{CO})(\mu\text{-CO})\{\mu\text{-}\eta^3\text{-C}(4\text{-C}_6\text{H}_4\text{CO}_2\text{H})\text{CHCNMe}_2\}]\text{CF}_3\text{SO}_3$, **[5]** CF_3SO_3 , containing a bridging carbyne, isocyanoacetate, or vinyliminium ligand, were investigated for their photoinduced cytotoxicity. Specifically, the novel water-soluble compounds **K[2]**, **[3]** NO_3 , and **[4]** CF_3SO_3 were synthesized and characterized by elemental analysis and IR and multinuclear NMR spectroscopy. Stereochemical aspects concerning **[4]** CF_3SO_3 were elucidated by ^1H NOESY NMR and single-crystal X-ray diffraction. Cell proliferation studies on human skin cancer (A431) and nontumoral embryonic kidney (HEK293) cells, with and without a 10-min exposure to low-power UV light (350 nm), highlighted the performance of the aminocarbyne **[3]** NO_3 , nicknamed **NIRAC** (Nitrate-Iron-Aminocarbyne), which is substantially nontoxic in the dark but shows a marked photoinduced cytotoxicity. Spectroscopic (IR, UV–vis, NMR) measurements and the myoglobin assay indicated that the release of one carbon monoxide ligand represents the first step of the photoactivation process of **NIRAC**, followed by an extensive disassembly of the organometallic scaffold.



1. INTRODUCTION

The search for new effective anticancer drugs based on transition metals is at the forefront of research and the design of photoactivable metal complexes is a promising strategy to enhance selectivity and reduce side effects.¹ Ideally, a nontoxic prodrug is injected and then activated by localized irradiation, resulting in the formation of reactive species finally leading to cell death.


Besides, the photoinduced release of carbon monoxide has been intensively studied in the last two decades due to the therapeutic effects provided by this small molecule in low concentrations,² and many different metal-based photoactivable CO-releasing molecules (photoCORM) have been studied in biological settings.^{3,4} Interestingly, some Mn(I), Re(I), and Ru(II) complexes manifested photoinduced antiproliferative activity on cancer cells or antimicrobial activity upon exposure to UV (305–365 nm)^{5,6} or visible (>440 nm)⁷ light for a relatively short time (typically 10–15 or 30–45 min, respectively). These biological effects have been often associated with the intracellular release of CO, although the role of the metal fragment deserves consideration.^{6,8}


Iron is an appealing candidate to design metal-based drugs, due to its biocompatibility, versatility, and low toxicity in many forms.⁹ Indeed, a number of monoiron(II) cyclopentadienyl and thiolate-bridging diiron(I) complexes have been investigated as CORMS or photoCORMS,^{3d} while ferrocene

derivatives recently emerged as promising anticancer and/or antimalarial agents.¹⁰ In this respect, the commercial $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ can be employed as a starting material to access robust cationic dinuclear derivatives by means of straightforward synthetic pathways. In more detail, thiocarbyne complexes are available from $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ by a reductive route which has been known since the 1970s (Scheme 1, path a).¹¹ Differently, thermal CO/CNR substitution affords neutral monoisocyanide derivatives as mixtures of terminal- and bridging-CNR isomers (path b);¹² subsequent nitrogen alkylation gives an aminocarbyne ligand which firmly occupies a bridging position (path c).¹³ Further CO removal, using the TMNO (trimethylamine-*N*-oxide) strategy, results in the formation of relatively stable acetonitrile complexes (path d)¹⁴ which, however, undergo MeCN substitution by a variety of monodentate ligands to yield cationic aminocarbyne derivatives (path e).¹⁵ Differently, in the presence of alkynes, acetonitrile displacement is followed by fast alkyne insertion

Received: February 14, 2022

Published: May 10, 2022



Scheme 1. Synthesis of Diiron Carbonyl Complexes with a Bridging Hydrocarbyl Ligand from $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]^+$ ^a

^a **a)** Thiocarbonyl complexes via preliminary reduction to $[\text{FeCp}(\text{CO})_2]^-$ ($\text{E} = \text{Me}, \text{Et}, \text{CF}_3\text{SO}_3^-$ or BF_4^- salts); ¹¹ **b)** isocyanide complexes ($\text{R} = \text{alkyl}$ or aryl); ¹² **c)** aminocarbonyl complexes (most frequently CF_3SO_3^- and also Cl^- , BF_4^- , and NO_3^- salts); ¹³ **d)** aminocarbonyl complexes with a labile acetonitrile ligand; ¹⁴ **e)** aminocarbonyl derivatives via acetonitrile substitution ($\text{L} = \text{phosphane}$, isocyanide, amine, imine, DMSO); ¹⁵ **f)** vinyliminium complexes via alkyne insertion into the Fe-carbyne bond ($\text{R}' = \text{alkyl}$, aryl , CO_2Me , SiMe_3 , pyridyl , thiophenyl ; $\text{R}'' = \text{H}$, Me , Et , Ph , CO_2Me ; CF_3SO_3^- salts). ¹⁶




Figure 1. Selected water-soluble diiron bis-cyclopentadienyl carbonyl compounds investigated in this work, bearing a thiocarbonyl (**[1]** CF_3SO_3^-), isocyanide (**[2]**; terminal isocyanide form not shown), aminocarbonyl (**[3]** NO_3^- , **[4]** CF_3SO_3^-), or vinyliminium (**[5]** CF_3SO_3^-) bridging ligand. Stereochemical details are specified for each compound.

into the iron–carbyne bond, according to a quite general reaction: note that over 100 diiron vinyliminium complexes with the general structure provided by path f) in Scheme 1 have been reported to date.¹⁶

Aminocarbonyl¹⁷ and vinyliminium¹⁸ complexes based on the $[\text{Fe}_2\text{Cp}_2(\text{CO})_x]$ ($x = 2, 3$) scaffold have been the subject of recent studies by some of us to assess their potential as anticancer agents. These compounds, aside from the metal element, show other ideal prerequisites for a pharmacological application such as simple and high-yielding preparation up to gram scale, appreciable solubility in water, amphiphilicity, and inertness in aqueous solution. Some aminocarbonyl and vinyliminium complexes revealed highly cytotoxic *in vitro* on various cancer cell lines, including 3D models, with a considerable degree of selectivity with respect to nontumoral cells. In general, the biological activity for each category of compounds is highly affected by the nature of the substituents on the bridging ligand, and quite often the most hydrophilic compounds are poorly cytotoxic. All diiron complexes are able to release carbon monoxide in an aqueous solution, albeit very slowly and only as a result of a prolonged thermal treatment (37 °C, 72 h; GC detected).^{17b,18c} Such a process is likely initiated by a thermally induced CO release step, and in the absence of suitable ligands in solution (e.g., DMSO), the decarbonylated organometallic scaffold undergoes fast dis-

assembly and aerobic oxidation, with concomitant formation of iron(III) oxides.^{17,18a} Notably, a significant increase of intracellular CO levels and reactive organic species (ROS) was detected upon treatment with the two most performing aminocarbonyl complexes, suggesting that their biological activity benefits from the combined effects provided by the metallic frame and the released carbon monoxide.^{2d,17b}

In light of these premises, we were interested in investigating whether diiron cyclopentadienyl complexes could be activated by irradiation, particularly those hydrophilic complexes known (or expected) to be scarcely cytotoxic otherwise. Herein we selected five complexes, one for each category illustrated in Scheme 1, including three novel compounds, for a preliminary investigation of their potential as photoactivable anticancer drugs.

2. RESULTS AND DISCUSSION

2.1. Synthesis and Characterization. The $\{\text{Fe}_2\text{Cp}_2\}$ complexes selected for the present investigation are reported in Figure 1. The preparation of the thiocarbonyl compound **[1]** CF_3SO_3^- from $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CS})]$ and ethyl triflate is described here for the first time, although other salts containing the same cation 1^+ were reported.^{11a,b} The vinyliminium compound **[5]** CF_3SO_3^- ^{18a} was prepared according to the literature. In these compounds, the net positive

charge associated with the organometallic scaffold combined with a suitable counteranion (CF_3SO_3^-) supplies an appreciable water solubility (*see below*). By contrast, neutral isocyanide compounds $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNR})]$ are generally insoluble in water. In this respect, potassium isocyanoacetate, easily obtained from the commercial ethyl ester (*see the Experimental Section*), combines the isocyanide function with a water-solubilizing group (carboxylate). Therefore, **K[2]** was synthesized in one step from $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ via CO/isocyanide exchange (*Scheme 1b*) in refluxing MeCN and isolated as a red-purple solid in 62% yield. Complex **2⁻** was previously obtained as the $[\text{K}(18\text{-crown-6})]^+$ salt from a more elaborated route, involving the preliminary photolytic generation of $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{NCMe})]$.¹⁹

Along the same line of thought, we decided to replace the typical CF_3SO_3^- anion in the aminocarbyne complex **3⁺** with the more hydrophilic NO_3^- . Note that, recently, we proposed the association of the nitrate anion to cationic ruthenium arene complexes resulting in a considerable improvement of the water solubility.²⁰ Therefore, methylation of $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNMe})]$ was carried out with excess CH_3I in CH_2Cl_2 , followed by alumina chromatography and a final ion metathesis step with AgNO_3 in MeOH. The novel compound **[3]NO₃**, nicknamed **NIRAC**, was isolated as a dark red solid in 70% yield.

Similarly, the phosphane PTA (1,3,5-triaza-7-phosphaadamantane) is a widely employed ligand to enhance the aqueous solubility of metal complexes.^{17,21} In this regard, the novel compound **[4]CF₃SO₃** was prepared from the tris-carbonyl precursor $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})\{\mu\text{-CNMe}(\text{Xyl})\}]\text{CF}_3\text{SO}_3$ via a classical two-step TMNO procedure (*Scheme 1d+e*); MeCN/phosphane exchange took place in refluxing THF, and the resulting dark green-brown solid was recovered by filtration in 87% yield. Compound **[4]CF₃SO₃** represents one of the few diiron derivatives containing the PTA ligand.^{17a,22}

Complexes **[1]CF₃SO₃**, **K[2]**, **[3]NO₃**, and **[4]CF₃SO₃** were characterized by elemental analysis and IR and multinuclear NMR spectroscopy; spectra are given in *Figures S1–S15* in the Supporting Information.

In **[1]CF₃SO₃**, the infrared carbonyl bands were detected at 2026, 2003, and 1837 cm^{-1} (CH_2Cl_2 solution), similar to those reported for the homologous tetrafluoroborate salt.^{11b} NMR spectra (acetone-*d*₆ solution) comprise a unique set of signals, indicating the *cis* arrangement adopted by the Cp ligands; inequivalence of the Cp, CO, and CH_2 groups is suggestive of hindered rotation around the $\mu\text{-C-S}$ bond.^{11a} The diagnostic ¹³C NMR resonance accounting for the carbyne falls at 406 ppm.


The IR spectra of **K[2]** (in the solid state and in the MeOH solution) are indicative of four isomers. Two bands of comparable intensity, ascribable to $\mu\text{-C-N}$ stretching (*e.g.*, 2140 and 1719 cm^{-1} in the solid state), are related to isomers containing a terminal or bridging isocyanide ligand (μ/t in *Figure 1*). On the other hand, two sets of carbonyl bands were recognized in each spectrum, suggesting the occurrence of *cis/trans* isomerism (with reference to the mutual geometry of the Cp's). In analogous $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNR})]$ complexes, *cis* and *trans* isomers were usually observed, interconverting into each other in solution via the Adams-Cotton mechanism.^{12,23} In the solid-state IR spectrum of **K[2]**, the higher frequency CO absorptions (1979, 1778) are less intense than those occurring at lower frequencies (1933, 1737), suggesting the prevalence of the *trans* isomers. The reverse situation was recognized in the

methanol solution, pointing out a prevalence of *cis* species, in agreement with the relatively high polarity of the medium.¹² The ¹H and ¹³C NMR spectra of **K[2]** in CD_3OD and $\text{DMSO-}d_6$ display broadened resonances, in alignment with the different isomers undergoing a fluxional process on the NMR time scale.

The IR and ¹H/¹³C NMR features of **[3]NO₃** in the MeCN or D₂O solution, respectively, resemble those of the related triflate salt.¹³ The dominant *cis* isomer is accompanied by a minor amount (*ca.* 10%) of the *trans* isomer.²⁴ The nitrate anion manifests itself with an intense and broad absorption at 1338 cm^{-1} in the solid-state IR spectrum and a diagnostic ¹⁴N NMR resonance at −5 ppm in D₂O. Interestingly, the carbonyl and N–C(carbyne) stretching wavenumbers of **3⁺** in the solid state are significantly affected by the anion (2021, 1991, 1814, 1592 *vs.* 1992, 1972, 1825, 1607 cm^{-1} for CF_3SO_3^- and NO_3^- salts, respectively; *Figure S3*).

In the solid-state IR spectrum of **[4]CF₃SO₃**, intense bands at 1992 and 1810 cm^{-1} are due to the terminal and bridging carbonyls, respectively, and a medium intensity band at 1506 cm^{-1} has been attributed to the N–C(carbyne) stretching. The NMR spectra of **[4]CF₃SO₃** in acetone-*d*₆ contain two sets of resonances, corresponding to *cis-Z* and *cis-E* diastereomers (10:1 ratio, by ¹H NMR), differing in the relative orientation of the *N*-substituents with respect to the $\mu\text{-C-N}$ bond, which holds some double bond character. For instance, two signals are present in the ³¹P spectrum, related to the PTA ligand (*Z*: −18.9 ppm, *E*: −22.8 ppm). The stereochemistry was unequivocally assigned by ¹H NOESY experiments, upon irradiation of each cyclopentadienyl (*Figures S14 and S15*), taking advantage of the spin–spin coupling to identify the Cp adjacent to the phosphorus atom (labeled Cp^p, ³J_{HP} ≈ 1.5 Hz); the results are summarized in *Scheme 2*. Briefly, NOE effects between Cp ligands were

Scheme 2. Structures of *cis-E* (a) and *cis-Z* (b) Diastereomers of **4⁺**



^aSubstituents/groups with the highest priority according to CIP rules are highlighted in green. NOE effects observed upon irradiation of the cyclopentadienyl bonded to the $\{\text{Fe}(\text{CO})\}$ (red) or the $\{\text{Fe}(\text{PTA})\}$ unit (blue) are represented by the arrows. Selected ¹H NMR chemical shifts (ppm) are reported next to each group (d for doublet).

observed for both isomers, confirming their localization on the same side of the $\text{Fe}_2(\mu\text{-C})_2$ unit (*cis* stereochemistry), while other NOE peaks indicated their proximity to *N*-CH₃, *N*-xyllyl, or PCH₂ groups. Thus, the *cis-Z* isomer, featuring the Xyl substituent on the aminocarbyne ligand pointing toward the PTA ligand, is the major isomer in the solution. Interestingly, in the *E* isomer, the Cp next to the carbonyl ligand resonates at a lower chemical shift with respect to Cp^p (4.72 and 5.32 ppm, respectively), while the opposite is observed for the *Z* counterpart (5.51, 4.87 ppm).

The structure of **[4]CF₃SO₃·0.5CH₃CN** was ascertained by a single-crystal X-ray diffraction study (*Figure 2*). The




Figure 2. View of the structure of the cation within *cis-Z*-[4] $\text{CF}_3\text{SO}_3 \cdot 0.5\text{CH}_3\text{CN}$. Displacement ellipsoids are at the 50% probability level. Hydrogen atoms have been omitted for clarity. Main bond distances (Å) and angles (deg): Fe(1)–Fe(2) 2.4985(5), Fe(1)–C(1) 1.765(3), Fe(1)–C(2) 1.957(3), Fe(2)–C(2) 1.899(3), Fe(1)–C(3) 1.885(3), Fe(2)–C(3) 1.855(3), Fe(2)–P(1) 2.1974(7), C(1)–O(1) 1.133(3), C(2)–O(2) 1.169(3), C(3)–N(1) 1.308(3), Fe(1)–C(1)–O(1) 174.7(2), Fe(1)–C(2)–Fe(2) 80.74(11), Fe(1)–C(3)–Fe(2) 83.83(11), Fe(1)–C(3)–N(1) 132.24(19), Fe(2)–C(3)–N(1) 143.7(2), C(3)–N(1)–C(4) 123.7(2), C(3)–N(1)–C(5) 122.6(2), C(4)–N(1)–C(5) 113.7(2).

structure of the cation 4^+ closely resembles that previously reported for $[\text{Fe}_2\text{Cp}_2(\text{CO})(\text{PTA})(\mu\text{-CO})(\mu\text{-CNMe}_2)]^+$, being the main bonding parameters are very similar.^{17a} The organometallic cation shows the *Z* stereochemistry, as also found in the crystal structure of the analogous diphenylphosphane derivative $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\text{PPh}_2\text{H})\{\mu\text{-CNMe}(\text{Xyl})\}]\text{-CF}_3\text{SO}_3$.^{15b} It should be remarked that, by contrast, the xylyl group and various N-, S-, or C-donor ligands (L) are usually located on opposite directions (*E* stereochemistry) in the

solid-state structures of $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\text{L})\{\mu\text{-CNMe}(\text{Xyl})\}]^+$ complexes.²⁵

Aqueous solubility (21 °C) of [1] CF_3SO_3 , [4] CF_3SO_3 , and [5] CF_3SO_3 ranges from 1 to 6 mmol·L^{−1}; these values are suited for biological applications (*cf.* the reported water solubility of the anticancer drug cisplatin is 8.4 mmol·L^{−1}).²⁶ Instead, K[2] (>0.5 mol·L^{−1}) and [3] NO_3 (≥ 0.11 mol·L^{−1}; *ca.* 3.4-fold increase with respect to the CF_3SO_3^- salt^{17a}) are much more soluble, confirming the beneficial role played by K^+ and NO_3^- as counterions in this respect.

The cationic complexes remain intact in water, with the ¹H NMR spectra in D₂O showing only resonances due to the starting material (Figures S18–S22). Two sets of signals of comparable intensity are present in the ¹³C NMR spectrum of a concentrated solution of K[2] (Figure S23), representing terminal/bridging coordination isomers. For instance, the isocyanide carbon and the methylene group give rise to resonances at 160/48 ppm for $[\text{Fe}_2\text{Cp}_2(\mu\text{-CO})_2(\text{CO})(\text{CNCH}_2\text{CO}_2)]^-$ and 267/65 ppm for $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CNCH}_2\text{CO}_2)]^-$, respectively, as expected for a terminal and a bridging isocyanide, respectively.¹² Solutions of the diiron compounds in water show medium-intensity absorptions ($\epsilon \approx 3\text{--}5 \cdot 10^3 \text{ M}^{-1}\text{cm}^{-1}$) in the UV region (308–340 nm); bands in the visible range extend up to 600 nm but are rather weak (Figure S24).

2.2. Spectroscopic Studies under UV Irradiation. The behavior of the complexes upon irradiation was investigated, in order to identify possible photoactivation processes. First, a solution of [3] NO_3 in water was exposed to 350 nm light (up to 135 min) and monitored by UV–vis spectroscopy. Under such conditions, the absorptions at 342 and 533 nm were progressively replaced by new bands at 360, 420, and 470 nm (Figure 3a). These changes are appreciable even after a very short irradiation time (<1 min). By comparison, no variation of the UV–vis spectrum was observed when the same solution was kept in the dark for at least one month, demonstrating the marked inertness of the complex in an aqueous solution at room temperature.

UV–vis data were treated with the Multivariate Curve Resolution-Alternating Least Squares (MCR-ALS) method,




Figure 3. (a) UV/vis spectra recorded on a solution of [3] NO_3 , NIRAC (150 μM) in H_2O after different times of exposure to 350 nm radiation ($E_v \sim 6 \text{ mW}/\text{cm}^2$) at 25 °C. (b) Concentration profiles for 3^+ (A) and the associated photoproducts (B and C), derived by fitting the experimental data using MCR-ALS analysis. $k_1 = 0.65 \pm 0.06 \text{ min}^{-1}$ and $k_2 = 0.135 \pm 0.008 \text{ min}^{-1}$.

and two kinetic processes were identified (Figure 3b). The determined values of k_n are considered conditional rate constants and constitute a good evaluation of the quantum yield under comparable measurement conditions and similar extinction coefficients (see the Experimental Section).^{5c}

On the other hand, only a progressive decrease of intensity of the ^{13}C NMR resonances belonging to 3^+ was observed for a D_2O solution of $[3]\text{NO}_3$ exposed to 350 nm radiation, even after 4 h (Figure S25).

The absence of new NMR signals is not surprising, if compared to the aerobic oxidative process ascertained in an aqueous solution at 37 °C (see the Introduction). In fact, no cyclopentadienyl complex other than the starting material was ever detected in a solution by NMR and no organic material was present in the final iron-containing precipitate, judging by IR and RAMAN analyses.^{17,18} In this regard, the release of cyclopentadiene (CpH) from $[\text{FeCpX}(\text{CO})_2]$ ($\text{X} = \text{Cl}, \text{Br}, \text{I}$) in an aqueous solution by blue-light irradiation was reported.²⁷

Since the above-mentioned thermal decomposition pathway of aminocarbene complexes entails their complete decarbonylation (see the Introduction), we investigated the release of carbon monoxide from $[3]\text{NO}_3$ promoted by UV irradiation. The myoglobin assay monitors spectroscopically the conversion of deoxy-myoglobin (Mb) to carbonmonoxy-myoglobin (MbCO).²⁸ A fresh solution of $[3]\text{NO}_3$ and reduced myoglobin was incubated in the dark for 15 min and then exposed to 350 nm light ($E_v = 6 \text{ mW}/\text{cm}^2$) at 25 °C while being monitored by UV–vis spectroscopy. A 4-fold excess of Mb to $[3]\text{NO}_3$ was chosen, to ensure one protein for each carbonyl that can potentially be released from the metal coordination sphere. New bands at 540 and 577 nm, diagnostic of MbCO , grew with increasing irradiation time, while the intensity of the Q-band at 557 nm of Mb decreased (Figure 4). The formation of Mb into MbCO was followed until no more spectral changes in the Q-band were observed (150 min). At this point, about 38 μM MbCO was formed, corresponding to ca. 2.2 equivalents of CO released from $[3]\text{NO}_3$.




Figure 4. Time-dependent formation of carbonmonoxy-myoglobin (MbCO) upon excitation at 350 nm ($E_v = 6 \text{ mW}/\text{cm}^2$, 25 °C) of a solution of $[3]\text{NO}_3$, NIRAC (17 μM), sodium dithionite (8 mM), and myoglobin (Mb, 68 μM) in 10 mM PBS buffer under nitrogen atmosphere. The inset shows the corresponding UV/vis spectral changes in the Q-band region, representative of Mb to MbCO conversion.


In another experiment, a solution of $[3]\text{NO}_3$ in water spiked with DMSO (0.8% v/v) was exposed to 350 nm radiation ($E_v \approx 6 \text{ mW}/\text{cm}^2$) at 37 °C for a variable time (0–60 min), followed by lyophilization and analysis of the residue via IR (ATR) spectroscopy. The carbonyl stretching bands of 3^+ (1990, 1971, and 1823 cm^{-1}) progressively decreased with irradiation time, along with the appearance of new bands around 1985 and 1799 cm^{-1} (Figure S26). These changes are consistent with the formation of $[\text{Fe}_2\text{Cp}_2(\text{CO})(\text{DMSO})(\mu\text{-CO})(\mu\text{-CNMe}_2)]^+$, 6^+ , upon CO/DMSO replacement, and are appreciable after 10-min irradiation.²⁹ In this respect, complex 6^+ was prepared in one step from $[3]\text{CF}_3\text{SO}_3$, $\text{Me}_3\text{NO} \cdot 2\text{H}_2\text{O}$, and DMSO in refluxing THF, purified by alumina chromatography and isolated as $[6]\text{CF}_3\text{SO}_3$ in 75% yield (see the Experimental Section and Figures S5, S16, and S17).

Despite the collected data being far from exhaustive, a parallel could be traced between the thermal and photoactivation of the tricarbonyl aminocarbene 3^+ (Scheme 3). Electronic excitation in water triggers a rapid, presumably complete disruption of the diiron framework, with a huge acceleration with respect to thermal effects alone (cf. 86% of intact $[3]\text{NO}_3$ in a solution after 72 h at 37 °C; see the Experimental Section). Conversely, in the presence of DMSO, the reactive species formed by photoinduced cleavage of one carbonyl ligand can, in part, be trapped (stabilized) by sulfoxide coordination.

Likewise, changes in the solid-state IR spectra of the tricarbonyl thiocarbene $[1]\text{CF}_3\text{SO}_3$ (0.8% v/v DMSO in water) following exposure to 350 nm radiation could be tentatively assigned to a CO/DMSO exchange process. However, jointly with $\text{K}[2]$ and $[5]\text{CF}_3\text{SO}_3$ (in a MeCN or H_2O solution, respectively), only minor changes in the IR spectra are observed in the first 10 min (Figures S27–S29). Instead, irradiation of the dicarbonyl PTA-substituted aminocarbene $[4]\text{CF}_3\text{SO}_3$ (in MeCN) caused substantial variations in the carbonyl absorption pattern, accompanied by the appearance of new bands at 2010 and 2056 cm^{-1} (Figure S30) suggestive of the formation of a piano-stool $\text{Fe}(\text{II})$ complex by oxidative cleavage of the $\text{Fe}(\text{I})$ – $\text{Fe}(\text{I})$ precursor.³⁰ For instance, bands at 2005 and 2047 cm^{-1} were reported for the related $[\text{Fe}(\eta^5\text{-indenyl})(\text{CO})_2(\text{PTA})]^+$.^{30b} These data indicate that dicarbonyl aminocarbene cations may undergo a different photoactivation mechanism compared to their tricarbonyl precursors.

The highest carbonyl stretching wavenumber, in a CH_2Cl_2 or MeOH solution, decreases along the following sequence: $[1]\text{CF}_3\text{SO}_3$ (2038 cm^{-1}) > $[3]\text{NO}_3$ (2022 cm^{-1}) > $[5]\text{-CF}_3\text{SO}_3$ (1993 cm^{-1}) > $\text{K}[2]$ (1991 cm^{-1}) > $[4]\text{CF}_3\text{SO}_3$ (1977 cm^{-1}). Based on this scale, the sensitivity to 350 nm irradiation is not correlated with the Fe – CO bond strength.³⁰ Looking at the electronic transitions in an aqueous solution, the photoactivable aminocarbene complexes 3^+ and 4^+ display an absorption peak (λ_{max} 340 nm) close to the irradiation wavelength (350 nm), while compounds that are minimally photoresponsive (1^+ , 2^- , and 5^+) are characterized by blue-shifted absorptions (311, 335, and 308 nm, respectively). Thus, 350 nm radiation is sufficient to activate 3^+ and 4^+ , while a higher energy UV treatment would probably be required for the other complexes.

2.3. Cell Proliferation. Proliferation experiments were carried out on A431 (human skin cancer) and HEK293 (nontumoral human embryonic kidney) cells treated with increasing concentrations (0–100/125 μM) of the diiron

Scheme 3. Activation Processes of the Aminocarbonyl 3^+ with Reference to Identified Products Only^a

^aThermal (a) and photolytic (b) disassembly in an aqueous solution and thermochemical (c) and photolytic (d) CO/DMSO replacement in a water/DMSO solution.




Figure 5. MTS assays of $[1]\text{CF}_3\text{SO}_3$ (0–100 μM) in A431 (a) and HEK293 (b) cells with or without a 10-min exposure to 350 nm radiation ($E_v = 6 \text{ mW}/\text{cm}^2$). Cell viability was measured after 24 and 48 h, respectively, at 37 $^\circ\text{C}$, and expressed relative to untreated cells (ANOVA at $\alpha = 0.05$). IC_{50} (A431 cells, 48 h) $\approx 49 \mu\text{M}$ (dark), $52 \mu\text{M}$ (irradiated). IC_{50} (HEK293 cells, 48 h) $\approx 32 \mu\text{M}$ (dark), $33 \mu\text{M}$ (irradiated).




Figure 6. MTS assays of $[3]\text{NO}_3$, NIRAC, (0–125 μM) in A431 (a) and HEK293 (b) cells with or without a 10-min exposure to 350 nm radiation ($E_v = 6 \text{ mW}/\text{cm}^2$). Cell viability was measured after 24 and 48 h, respectively, at 37 $^\circ\text{C}$, and expressed relative to untreated cells (ANOVA at $\alpha = 0.05$). IC_{50} (A431 cells, 48 h) $> 125 \mu\text{M}$ (dark), $\approx 90 \mu\text{M}$ (irradiated). IC_{50} (HEK293 cells, 48 h) $> 125 \mu\text{M}$ (dark), $70 \mu\text{M}$ (irradiated).

compounds dissolved in water/DMSO 0.8% v/v ($[1]\text{CF}_3\text{SO}_3$, $[4]\text{CF}_3\text{SO}_3$, $[5]\text{CF}_3\text{SO}_3$) or PBS ($\text{K}[2]$, $[3]\text{NO}_3$). Experiments were performed in 48-well plates exposed to 350 nm radiation ($E_v \approx 6 \text{ mW}/\text{cm}^2$) for 10 min at 37 $^\circ\text{C}$. Controls (without addition of diiron complexes) were likewise treated with water/DMSO or PBS, kept in the dark, or irradiated. Cell

viability was assessed with the MTS assay after 24 and 48 h of incubation at 37 $^\circ\text{C}$; results are displayed in Figures 5, 6, and S31–S37.

Compound $[1]\text{CF}_3\text{SO}_3$ is moderately cytotoxic on both cell lines kept in the dark (IC_{50} after 48 h: $50 \mu\text{M}$ on A431, $30 \mu\text{M}$ on HEK293; Figure 5). The other complexes are substantially

nontoxic without exposure to 350 nm radiation against A431 cancer cells up to the maximum concentration tested.

A similar scenario is observed for nonirradiated HEK293 cells, except for a significant reduction in cell viability upon treatment with the highest concentrations (60–100 μM) of $\text{K}[2]$ for 48 h and a more modest effect for $[4]\text{CF}_3\text{SO}_3$ in the same conditions. Overall, cell viability profiles (dark cytotoxicity) for $[1]\text{CF}_3\text{SO}_3$, $[3]\text{NO}_3$, and $[5]\text{CF}_3\text{SO}_3$ resemble those previously found on other cancerous and noncancerous cell lines for the same species (3^+ as CF_3SO_3^- salt).^{17a,18a}

Exposure to 350 nm radiation resulted in minor differences in A431 and HEK293 cell viability for $[1]\text{CF}_3\text{SO}_3$, $\text{K}[2]$, and $[5]\text{CF}_3\text{SO}_3$, up to the maximum concentration tested, in agreement with their modest or absent response to 350 nm irradiation (see above).³¹ Conversely, a marked decrease in viability (>50%) was ascertained for A431 cells treated with $[3]\text{NO}_3$, **NIRAC** (100 and 125 μM), the same compound being inactive in the absence of irradiation under the same conditions (Figure 6a). Compound $[3]\text{NO}_3$ manifested a photoinduced cytotoxicity also toward nontumoral HEK293 cells (Figure 6b); in this respect, higher sensitivity of this cell line to carbon monoxide was previously reported.^{5c} Note that the irradiation time used for cell viability experiments is compatible with the kinetics of the photoactivation of $[3]\text{NO}_3$ (see Figures 3 and 4), indicating that the photoproducts are responsible for cytotoxicity.

A decrease in viability of A431 cells upon irradiation can be also noticed for $[4]\text{CF}_3\text{SO}_3$ after a 24-h incubation ($\geq 60 \mu\text{M}$; Figure S34a); nevertheless, the higher viability observed after 48 h suggests caution on interpreting these data.

3. CONCLUSIONS

Here, we have presented one of the first studies on the photoinduced cytotoxicity of cyclopentadienyl diiron complexes. More specifically, five hydrophilic compounds with different bridging hydrocarbyl ligands were investigated for their antiproliferative activity and photoactivation under UV irradiation. This series includes three novel compounds, which were designed to enhance the aqueous solubility. The tricarbonyl aminocarbyne compound **NIRAC**, readily accessible in multigram scales from inexpensive precursors and very soluble in water thanks to the nitrate anion, emerged with the best performance, being nontoxic in the dark but able to decrease cell viability in a dose-dependent manner upon irradiation at 350 nm. In detail, photoexcitation of **NIRAC** using low power near-UV light promotes carbon monoxide release which triggers the fast disruption of the diiron framework, according to kinetics well-fitting the short irradiation treatment (10 min) used in cellular studies. The other compounds manifested a lower sensitivity to irradiation in terms of cellular effects, which is not correlated to their Fe–CO bond strength (IR spectra). These preliminary results encourage further studies on the photoactivation of diiron complexes based on the $\{\text{Fe}_2\text{Cp}_2\}$ core in the medicinal (anticancer) setting, taking advantage of their easy availability and wide structural variability³² to design new compounds that can be activated by longer, biocompatible wavelengths.


4. EXPERIMENTAL SECTION

4.1. General Experimental Details. $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ (99%) was purchased from Strem Chemicals; other reactants and solvents were obtained from Alfa Aesar, Merck, Apollo Scientific, or TCI Chemicals and were of the highest purity available. Ethyl triflate and methyl

iodide (4 $^\circ\text{C}$), ethyl isocynoacetate ($-20 \text{ }^\circ\text{C}$), and 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (PTA) were stored under N_2 . Contaminated labware was treated with NaOH/EtOH (alkylating agents) or HCl/EtOH (isocyanides). Complexes $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CS})]$,³³ $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNMe})]$,¹² $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})\{\mu\text{-CNMe}(\text{Xyl})\}]\text{CF}_3\text{SO}_3$,¹³ and $[\text{Fe}_2\text{Cp}_2(\text{CO})(\mu\text{-CO})\{\mu\text{-}\eta^1\text{:}\eta^3\text{-C}(4\text{-C}_6\text{H}_4\text{CO}_2\text{H})\text{CHCNMe}_2\}]\text{CF}_3\text{SO}_3$ ($[5]\text{CF}_3\text{SO}_3$)^{18a} were prepared according to published procedures. The synthesis of $[1]\text{CF}_3\text{SO}_3$, $\text{K}[2]$, and $[3]\text{NO}_3$ was carried out under dry N_2 using standard Schlenk techniques and solvents distilled over appropriate drying agents (MeCN from CaH_2 , CH_2Cl_2 from P_2O_5). The synthesis of potassium isocynoacetate, $[4]\text{CF}_3\text{SO}_3$, and $[6]\text{CF}_3\text{SO}_3$ was carried out under N_2 using deaerated solvents. All the other operations were conducted under air with common laboratory glassware. Chromatographic separations were carried out on neutral alumina columns (Merck). NMR spectra were recorded at 25 $^\circ\text{C}$ on a Bruker Avance II DRX400 instrument equipped with a BBFO broadband probe. Chemical shifts are referenced to the residual solvent peaks (^1H , ^{13}C) or to external standards (^{14}N to CH_3NO_2 , ^{19}F to CFCl_3 , ^{31}P to 85% H_3PO_4).³⁴ ^1H and ^{13}C spectra were assigned with the assistance of $^1\text{H}\{^{31}\text{P}\}$, ^1H NOESY, and $^1\text{H}\text{--}^{13}\text{C}$ gs-HSQC experiments. NMR signals due to minor isomers are italicized. IR spectra of solid samples ($650\text{--}4000 \text{ cm}^{-1}$) were recorded on a PerkinElmer Spectrum One FT-IR spectrometer equipped with a UATR sampling accessory; IR spectra of solutions were recorded on a PerkinElmer Spectrum 100 FT-IR spectrometer using a CaF_2 liquid transmission cell ($2300\text{--}1500 \text{ cm}^{-1}$). IR and UV–vis spectra were processed with Spectragryph software.³⁵ Carbon, hydrogen, nitrogen, and sulfur analyses were performed on a Vario MICRO cube instrument (Elementar).

4.2. Synthesis and Characterization of Compounds. $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CSEt})]\text{CF}_3\text{SO}_3$, $[1]\text{CF}_3\text{SO}_3$ (Chart 1). The

Chart 1. Structure of 1^+




synthesis of related tetrafluoroborate and iodide salts was previously reported.^{11a,b} The CF_3SO_3^- salt was reported without the synthetic procedure.³⁶ Compound $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CS})]$ (ca. 0.6 mmol, in admixture with $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$) was dissolved in anhydrous CH_2Cl_2 (8 mL) under N_2 and treated with $\text{CF}_3\text{SO}_3\text{Et}$ (0.10 mL, 0.77 mmol). The dark-red mixture was stirred for 6 h at room temperature and then transferred on top of an alumina column (h 3, d 3.4 cm). Impurities were eluted with neat CH_2Cl_2 and THF, and then a red band was collected with MeCN . Volatiles were removed under vacuum, and the residue was triturated after prolonged soaking in $\text{Et}_2\text{O}/\text{hexane}$ (1:1 v/v mixture, 50 mL). The suspension was filtered; the resulting carmine red solid was washed with $\text{Et}_2\text{O}/\text{hexane}$ and dried under vacuum (40 $^\circ\text{C}$). Yield: 214 mg, 65%. Soluble in CH_2Cl_2 , CHCl_3 , acetone, MeCN , sparingly soluble in Et_2O , insoluble in hexane. Anal. Calcd for $\text{C}_{17}\text{H}_{15}\text{F}_3\text{Fe}_2\text{O}_6\text{S}_2$: C: 37.25, H: 2.76, S: 11.70. Found: 37.10, H: 2.61, S: 11.52. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3102w, 2974w, 2938w, 2026s (CO), 2003s (CO), 1837s ($\mu\text{-CO}$), 1454w, 1432w, 1420w, 1382w, 1362w, 1275s-sh, 1258s (SO_3), 1225s-sh (SO_3), 1152s (SO_3), 1029s (CS), 999s-sh, 973w, 910w, 860m, 850m, 767w, 755w, 700m-sh, 688s. IR (CH_2Cl_2): $\tilde{\nu}/\text{cm}^{-1}$ = 2038s (CO), 2007m-sh (CO), 1850m ($\mu\text{-CO}$). IR (MeCN): $\tilde{\nu}/\text{cm}^{-1}$ = 2038s (CO), 2006m-sh (CO), 1850m ($\mu\text{-CO}$). ^1H NMR (acetone- d_6): δ/ppm = 5.72, 5.64 (s, 10H, Cp); 4.41, 4.17 (dq, $^2J_{\text{HH}}$ = 14.8 Hz, $^3J_{\text{HH}}$ = 7.5 Hz, 2H, CH_2); 1.67 (t, $^3J_{\text{HH}}$ = 7.6 Hz, 3H, CH_3). No changes in

the ^1H NMR spectrum were observed after 14 h at room temperature. $^{13}\text{C}\{^1\text{H}\}$ NMR (acetone- d_6): δ/ppm = 405.5 (CS); 252.2 ($\mu\text{-CO}$); 208.1, 207.9 (CO); 122.5 (d, $^1J_{\text{CF}}$ = 322 Hz, CF_3); 93.0, 92.3 (Cp); 50.5 (CH_2), 13.5 (CH_3). $^{19}\text{F}\{^1\text{H}\}$ NMR (acetone- d_6): δ/ppm = -78.8 .

Potassium 2-Isocyanoacetate, $\text{K}[\text{C}\equiv\text{NCH}_2\text{CO}_2]$ (Chart 2). The title compound was prepared according to a modified literature


Chart 2. Structure of $[\text{C}\equiv\text{NCH}_2\text{CO}_2]^-$



procedure.³⁷ A solution of KOH (395 mg, 7.0 mmol) in water (1 mL) was added to a solution of ethyl isocyanoacetate (0.76 mL, 6.95 mmol) in THF (10 mL) under N_2 . The pale orange suspension was stirred for 5 h at room temperature under protection from the light. The final mixture (two pale yellow immiscible liquids) was dried under vacuum, and the residue was triturated in MeCN (20 mL). The suspension was filtered; the resulting colorless solid was thoroughly washed with MeCN and then Et_2O and dried under vacuum at 40°C , over P_2O_5 . Yield: 755 mg, 88%. The solid was kept under N_2 at -20°C for long-term storage. Soluble in water, MeOH, DMSO; insoluble in all other common organic solvents. Anal. Calcd for $\text{C}_3\text{H}_2\text{KNO}_2$: C, 29.26; H, 1.64; N, 11.37. Found: C, 28.51; H, 1.78; N, 11.21. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3505w, 3330w, 3246w, 2174w-sh, 2157s (CN), 1609s-br ($\text{CO}_{2,\text{asym}}$), 1577s-sh, 1428w, 1417w, 1394s ($\text{CO}_{2,\text{sym}}$), 1369s, 1296s, 1261w, 1236w, 972m, 902s, 696s. IR (MeOH): $\tilde{\nu}/\text{cm}^{-1}$ = 2177w-sh (CN), 2156m (CN), 1636s (CO_2). ^1H NMR (DMSO- d_6): δ/ppm = 3.70 (s, CH_2). ^1H NMR (CD_3OD): δ/ppm = 4.05 (s, CH_2). $^{13}\text{C}\{^1\text{H}\}$ NMR (CD_3OD): δ/ppm = 170.4 (CN), 44.4 (m*, CH_2) [$^*\text{H/D}$ exchange]. Commercially available potassium isocyanoacetate (Merck, 85%) contains *potassium N-formyl glycinate*, which cannot be easily removed due to similar solubility properties. ^1H NMR (CD_3OD): δ/ppm = 8.07 (s, 1H, HCO), 3.77 (s, 2H, CH_2).

$\text{K}[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNCH}_2\text{CO}_2)]$, $\text{K}[2]$ (Chart 3). The organometallic anion was previously isolated as the $[\text{K}(18\text{-crown-6})]^+$ salt in a two-

Chart 3. Structures of 2^{-a}




^aWavy bonds represent *cis/trans* isomerism.

step procedure with $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{NCMe})]$ as the intermediate.¹⁹ In a Schlenk flask under N_2 , a mixture of $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$ (283 mg, 0.80 mmol) and potassium 2-isocyanoacetate (99 mg, 0.80 mmol) in anhydrous MeCN (6 mL) was stirred at reflux for 5 h. The resulting suspension (red solid and dark red solution) was filtered over a Celite column, and the solid was washed thoroughly with MeCN and Et_2O , to ensure complete removal of unreacted $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$. Next, the solid on the column was dissolved and eluted using deaerated MeOH under N_2 . The methanolic eluate was dried under vacuum, affording a raspberry red/purple glassy solid. Yield: 222 mg, 62%. The solid was kept under N_2 for long-term storage (hygroscopic). The reaction is very sensitive to moisture: rigorously anhydrous MeCN is required. The addition of protic species (e.g., MeOH, $[\text{Et}_3\text{NH}]\text{Cl}$) results in complete recovery of $[\text{Fe}_2\text{Cp}_2(\text{CO})_4]$, likely due to the instability of $\text{CNCH}_2\text{CO}_2\text{H}$.³⁸ Soluble in water, MeOH, EtOH, DMSO, poorly soluble in DMF, insoluble in MeCN, CH_2Cl_2 , Et_2O , and other

common organic solvents. Anal. Calcd for $\text{C}_{16}\text{H}_{12}\text{Fe}_2\text{KNO}_5$: C, 42.79; H, 2.69; N, 3.12. Found: C, 42.22; H, 2.88; N, 3.05. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3111w, 2967w, 2931w; 2202w-sh*, 2140s ($\text{C}\equiv\text{N}$); 1979m-sh, 1933s (CO); 1778m-sh, 1737s-sh ($\mu\text{-CO}$); 1719s ($\mu\text{-CN}$); 1618s, 1595s ($\text{CO}_{2,\text{asym}}$); 1417m, 1370s ($\text{CO}_{2,\text{sym}}$), 1286s, 1114w, 1059w, 1012m, 1004m, 977w, 900w, 839m-sh, 817m, 969w. IR (MeOH): $\tilde{\nu}/\text{cm}^{-1}$ = 2204*w-sh, 2106m ($\text{C}\equiv\text{N}$); 1991s, 1951m (CO); 1797m, 1762w ($\mu\text{-CO}$); 1724m ($\mu\text{-CN}$), 1670m; 1635s ($\text{CO}_{2,\text{asym}}$) [$^*\text{CpFe}(\text{II})$ impurity]. ^1H NMR (DMSO- d_6): δ/ppm = 4.74, 4.66 (s-br, 10H, Cp); 4.03 (br, 2H, CH_2). $^{13}\text{C}\{^1\text{H}\}$ NMR (DMSO- d_6): δ/ppm = 279.3 ($\mu\text{-CO}$); 213.9 (CO); 165.0 (br, CO_2); 158.7, 156.3 (CN); 87.9, 87.1 86.4 (Cp); 50.0, 49.2 (br, CH_2). ^1H NMR (CD_3OD): δ/ppm = 4.97, 4.95 (s-br, 10H, Cp), 4.30 (s, 2H, ** CH_2) [** undergoes H/D exchange]. $^{13}\text{C}\{^1\text{H}\}$ NMR (CD_3OD): δ/ppm = 213br (CO), 170 (CN), 160.7 (CO_2), 88.8, 83.3 (Cp); the CH_2 signal is hidden by the solvent residual peak.

$[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CNMe}_2)]\text{NO}_3$, $[3]\text{NO}_3$, **NIRAC** (Chart 4). Compound $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNMe}_2)]\text{I}$ was prepared according to a

Chart 4. Structure of 3^{+a}



^aWavy bonds represent *cis/trans* isomerism.


modified literature procedure.³⁹ A solution of $[\text{Fe}_2\text{Cp}_2(\text{CO})_3(\text{CNMe})]\text{I}$ ¹² (ca. 3.5 mmol, from methyl isocyanide) in CH_2Cl_2 (30 mL) was treated with methyl iodide (1.3 mL, 22 mmol) and stirred at room temperature under N_2 for 72 h. The final solution was charged on an alumina column. Impurities were eluted using CH_2Cl_2 , and then a red fraction corresponding to $[\text{Fe}_2\text{Cp}_2(\text{CO})_2(\mu\text{-CO})(\mu\text{-CNMe}_2)]\text{I}$ was eluted with CH_3OH . AgNO_3 (594 mg, 3.5 mmol) was added to the eluted methanol solution; the mixture was stirred for 1 h, during which time progressive precipitation of a white solid (AgI) occurred. The final mixture was dried under reduced pressure. The residue was suspended in MeCN/ CH_2Cl_2 1:2 v/v and filtered through a Celite pad. Subsequent evaporation of the solvent under reduced pressure afforded a dark red solid, which was washed with Et_2O and hexane and dried under vacuum (40°C). Yield: 1087 mg, 70%. Soluble in water, MeOH, MeCN, less soluble in acetone, CH_2Cl_2 , insoluble in Et_2O , hexane. Anal. Calcd for $\text{C}_{16}\text{H}_{16}\text{Fe}_2\text{N}_2\text{O}_6$: C, 43.25; H, 3.63; N, 6.31. Found: C, 43.15; H, 3.57; N, 6.41. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3398br, 3112sh, 3081w-m, 2943w, 2870vw, 2211w, 2176w-m; 1992vs (CO), 1972vs (CO), 1940m-sh, 1825vs ($\mu\text{-CO}$), 1790m-sh, 1667w-m, 1607s ($\mu\text{-CN}$), 1448w, 1433w, 1418w, 1396m, 1366m-s, 1328br-vs (NO_3), 1191m-s, 1163m-s, 1116vw, 1067br-w, 1026m, 1008m, 952w, 860s, 829m, 760br-vs IR (MeCN): $\tilde{\nu}/\text{cm}^{-1}$ = 2022s (CO), 1989m (CO), 1833s ($\mu\text{-CO}$), 1603m ($\mu\text{-CN}$). ^1H NMR (CD_3OD): δ/ppm = 5.38, 5.26 (s, 10H, Cp); 4.31, 4.23 (s, 6H, NCH_3). ^1H NMR (D_2O): δ/ppm = 5.34, 5.22 (s, 10H, Cp); 4.27, 4.19 (s, 6H, NCH_3). Isomer (*cis/trans*) ratio (^1H NMR): 8.8 (CD_3OD), ca. 22 (D_2O). $^{13}\text{C}\{^1\text{H}\}$ NMR (D_2O): δ/ppm = 260.2 ($\mu\text{-CO}$); 207.6 (CO); 91.2, 89.7 (Cp); 53.5 (NCH_3); the signal for $\mu\text{-CN}$ falls outside the selected spectral window (>300 ppm). ^{14}N NMR (D_2O): δ/ppm = -5.1 (s, $\Delta\nu_{1/2}$ = 19 Hz, NO_3^-).

$[3]\text{CF}_3\text{SO}_3$.¹³ The solid-state IR was recorded for comparative purposes. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3126w, 3097w, 2945w, 2174w, 2021s (CO), 1991s (CO), 1958m-sh, 1814s ($\mu\text{-CO}$), 1774w-sh, 1592s ($\mu\text{-CN}$), 1454w, 1440w, 1422w, 1393m, 1279s-sh, 1257s

(SO₃), 1223s-sh (SO₃), 1186m, 1149s (SO₃), 1069w, 1031s, 1009m-sh, 881m-sh, 872m, 848m, 837m-sh, 761s, 755s-sh.

[Fe₂Cp₂(CO)(PTA)(μ-CO){μ-CNMe(Xyl)}]CF₃SO₃ (**Chart 5**). A solution of [Fe₂Cp₂(CO)₂(μ-CO){μ-CNMe(Xyl)}]CF₃SO₃ (**87**

Chart 5. Structure of 4⁺




^aNumbering refers to C atoms; wavy bonds represent *E/Z* isomerism.

mg, 0.14 mmol) and Me₃NO·2H₂O (17 mg, 0.15 mmol) in MeCN (5 mL) was stirred at room temperature under N₂. After 1 h, conversion was checked by IR, and then volatiles were removed under vacuum. The dark brown residue was dissolved in THF (10 mL), and PTA (24 mg, 0.15 mmol) was added. The solution was stirred at reflux temperature under N₂ for 2 h, progressively turning dark green with precipitate formation. Conversion was checked by IR and then the suspension was cooled at room temperature and filtered (G4 glass filter). The dark green-brown solid was washed with THF, Et₂O, and hexane and dried under vacuum (40 °C). Yield: 92 mg, 87%. Soluble in water, DMSO, MeCN, MeOH, poorly soluble in THF, CH₂Cl₂, acetone, ⁱPrOH; insoluble in toluene, Et₂O, hexane. X-ray quality crystals of [4]CF₃SO₃ (*Z* isomer) were obtained from a MeCN solution layered with Et₂O and settled aside at −20 °C. Anal. Calcd for C₂₉H₃₄F₃Fe₂N₄O₅PS: C, 46.42; H, 4.57; N, 7.47; S, 4.27. Found: C, 46.5; H, 4.44; N, 7.32; S, 4.36. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3101w, 3080w, 2952w, 2928w, 2880w, 1992s (CO), 1947w-sh (CO), 1810s (μ-CO), 1773w, 1506m-sh (μ-CN), 1494m, 1471w, 1448w, 1436w, 1417w, 1380m, 1290w, 1259s (SO₃), 1244s-sh, 1221s (SO₃), 1172m-sh, 1151s (SO₃), 1106m, 1084m, 1044w, 1027s, 1015s, 973s, 948s, 888m, 853m, 843m, 805m, 787m, 768s, 743m, 733s, 633s. IR (CH₂Cl₂): $\tilde{\nu}/\text{cm}^{-1}$ = 1977m (CO), 1794m (μ-CO). IR (MeCN): $\tilde{\nu}/\text{cm}^{-1}$ = 1974s (CO), 1792m (μ-CO), 1508w (μ-CN). ¹H NMR (acetone-*d*₆): δ/ppm = 7.50–7.40 (m, 3H, C³H + C⁴H); 5.51, 4.73 (s, 5H, Cp); 5.33, 4.87 (d, ³J_{HP} = 1.5 Hz, 5H, Cp^p); 4.58, 4.53 (s, 3H, NCH₃); 4.44–4.31 (m, 6H, NCH₂); 4.09 (s), 3.79, 3.68 (d/m, ²J_{HH} = 15 Hz) (6H, PCH₂); 2.79, 2.75, 2.41, 2.35 (s, 6H, C⁵H). Isomer (*Z/E*) ratio *ca.* 10 (¹H NMR, acetone-*d*₆). ¹³C{¹H} NMR (acetone-*d*₆): δ/ppm = 331.1 (d, ²J_{CP} = 14 Hz, μ-CN); 264.4 (d, ²J_{CP} = 19 Hz, μ-CO); 215.3 (CO); 149.1 (C¹); 135.2, 134.6, 133.7, 132.7 (C²); 131.1, 130.5 (C⁴); 130.3, 130.2, 130.18, 130.0 (C³); 90.9, 89.9 (Cp); 88.5, 87.8 (Cp^p); 72.9, 72.8 (d, ³J_{CP} = 7 Hz, NCH₂); 56.5, 56.1 (NCH₃); 55.5, 54.5 (d, ¹J_{CP} = 13 Hz, PCH₂); 20.0, 19.2, 19.0, 18.8 (C⁵). ¹⁹F{¹H} NMR (acetone-*d*₆): δ/ppm = −78.8. ³¹P{¹H} NMR (acetone-*d*₆): δ/ppm = −18.9, −22.8.

[Fe₂Cp₂(CO)(κS-DMSO)(μ-CO)(μ-CNMe₂)]CF₃SO₃, [**6**]CF₃SO₃ (**Chart 6**). A solution of [Fe₂Cp₂(CO)₂(μ-CO)(μ-CNMe₂)]CF₃SO₃ (121 mg, 0.228 mmol) and Me₃NO·2H₂O (17 mg, 0.15 mmol) in THF (8 mL) was treated with DMSO (0.10 mL, 1.4 mmol) and stirred at reflux under N₂. After 4 h, conversion was checked by IR (CH₂Cl₂), and the brown suspension was moved on top of an alumina column (h 4, d 2.3 cm). Impurities were eluted with THF, and then a dark green-brown band was eluted with MeOH/THF 2:1 *v/v*. Volatiles were removed under vacuum, and the residue was dissolved in CH₂Cl₂ and filtered over Celite. The filtrate was thoroughly dried under vacuum (40 °C) and then triturated in Et₂O. The suspension was filtered, and the resulting dark brown solid was washed with Et₂O and pentane and dried under vacuum (40 °C).

Chart 6. Structure of 6⁺



^aWavy bonds represent *cis/trans* isomerism.

Yield: 100 mg, 75%. Soluble in CH₂Cl₂, acetone; insoluble in Et₂O, pentane; soluble but not stable in CDCl₃. Anal. Calcd for C₁₈H₂₂F₃Fe₂NO₆S₂: C, 37.20; H, 3.82; N, 2.41; S, 11.03. Found: C, 37.28; H, 3.76; N, 2.37; S, 11.0. IR (solid state): $\tilde{\nu}/\text{cm}^{-1}$ = 3092w, 2981w, 2928w, 2178w, 1971s (CO); 1804m-sh, 1790s (μ-CO); 1592m (μ-CN), 1434w, 1420w, 1397m, 1364w, 1323w, 1257s (SO₃), 1224s-sh (SO₃), 1192m, 1141s (SO₃) 1093s-sh (SO), 1069m-sh, 1029s, 1013s-sh, 970m-sh, 856m, 843m, 757s, 680m. IR (CH₂Cl₂): $\tilde{\nu}/\text{cm}^{-1}$ = 2005s (CO), 1980m-sh (CO), 1804s (μ-CO), 1587m (μ-CN). IR (MeCN): $\tilde{\nu}/\text{cm}^{-1}$ = 2002s (CO), 1805s (μ-CO), 1587m (μ-CN). ¹H NMR (acetone-*d*₆): δ/ppm = 5.34, 5.28 (s, 5H, Cp); 5.21, 5.17 (s, 5H, Cp'); 4.61, 4.34 (s, 3H, NCH₃); 4.31, 4.27 (s, 3H, NCH₃); 3.58, 3.26 (s, 3H, SCH₃); 3.19, 3.03 (s, 3H, SCH₃). Isomer (*cis/trans*) ratio: *ca.* 19 (¹H NMR, acetone-*d*₆). ¹³C{¹H} NMR (acetone-*d*₆): δ/ppm = 326.5 (μ-CN); 268.0 (μ-CO); 212.4 (CO); 90.3 (Cp); 88.9 (Cp'); 54.8 (NMe'); 53.6 (NMe); 52.9 (SMe); 49.3 (SMe'). ¹⁹F NMR (acetone-*d*₆): δ/ppm = −78.7.

¹H/¹³C NMR and UV–Vis Spectra in Aqueous Solution. UV–vis spectra (250–800 nm) were recorded on an Ultraspex 2100 Pro spectrophotometer using PMMA cuvettes (1 cm path length).

[1]CF₃SO₃. UV (H₂O, 1.7 × 10^{−3} M): λ/nm ($\epsilon/\text{M}^{-1}\cdot\text{cm}^{-1}$) = 280sh (1.1·10⁴), 311sh (8.7·10³), 500sh (9.5·10²). ¹H NMR (D₂O): δ/ppm = 5.46, 5.41 (s, 10H, Cp); 4.19, 4.01 (m, 2H, CH₂); 1.62 (t, ³J_{HH} = 7.6 Hz, 3H, CH₃).

K[2]. UV (H₂O, 1.8 × 10^{−3} M): λ/nm ($\epsilon/\text{M}^{-1}\cdot\text{cm}^{-1}$) = 335 (4.6·10³), 510 (3.9·10²). ¹H NMR (D₂O) δ/ppm = 5.1, 4.9–4.8 (br, Cp), 4.5, 4.4 (br, CH₂). Two sets of signals are observed in the ¹³C{¹H} spectrum, ascribable to compounds with a bridging or terminal isocyanide ligand, by comparison with literature data.¹² [Fe₂Cp₂(μ-CO)₂(CO)(CNCH₂CO₂)][−]. ¹³C{¹H} NMR (D₂O): δ/ppm = 293.8 (μ-CO); 211.1 (CO); 171.8 (CO₂); 160.3 (CN); 87.9, 87.2 (Cp); 48.5 (CH₂). [Fe₂Cp₂(CO)₂(μ-CO)(μ-CNCH₂CO₂)][−]. ¹³C{¹H} NMR (D₂O): δ/ppm = 283.2 (μ-CO); 267 (br, μ-CN); 213 (br, CO); 178.3 (CO₂); 88.2 (Cp); 64.9 (CH₂).

[3]NO₃. UV (H₂O, 1.9 × 10^{−3} M): λ/nm ($\epsilon/\text{M}^{-1}\cdot\text{cm}^{-1}$) = 280sh (8.6·10³), 340 (5.5·10³), 481 (5.3·10²), 533sh (3.8·10²). ¹H NMR (D₂O): δ/ppm = 5.34, 5.22 (s, 10H, Cp); 4.27, 4.19 (s, 1H, 6H, NCH₃).

[4]CF₃SO₃. UV (H₂O, 3.7 × 10^{−4} M): λ/nm ($\epsilon/\text{M}^{-1}\cdot\text{cm}^{-1}$) = 340sh (3.0·10³), 422sh (9.0·10²), 510 (4.3·10²), 590 (3.1·10²). ¹H NMR (D₂O): δ/ppm = 7.50–7.32 (m, 3H, C₆H₅); 5.38, 5.15 (s, 5H, Cp); 4.73, 4.66 (s, Cp); 4.42–4.23 (m, 9H, NCH₃ + NCH₂); 3.92 (s), 3.67 (d, ²J_{HP} = 16.4 Hz), 3.60–3.53 (m) (6H, PCH₂); 2.68, 2.63, 2.30, 2.26 (s, 6H, NCH₃).

[5]CF₃SO₃. UV (H₂O, 7.5 × 10^{−4} M): λ/nm ($\epsilon/\text{M}^{-1}\cdot\text{cm}^{-1}$) = 268 (2.6 × 10⁴), 308sh (1.5 × 10⁴), 414sh (3.1 × 10³), 526 (7.5 × 10²), 607 (5.0 × 10²). ¹H NMR (D₂O): δ/ppm = 8.03, 7.78 (d, ³J_{HH} = 8.2 Hz, 4H, C₆H₄); 5.27, 5.13 (s, 10H, Cp); 4.62 (s, 1H, CH); 3.88, 3.33 (s, 6H, NCH₃).

Behavior of [3]NO₃ in Water at 37 °C over 72 h. The selected compound was dissolved in a D₂O solution containing Me₂SO₂ (4.0 × 10^{−3} M, 0.7 mL). The red solution (*c*_{Fe₂} ≈ 10^{−2} M) was filtered over Celite and analyzed by ¹H NMR (delay time = 10 s; number of scans = 20). Next, the solution was heated at 37 °C for 72 h, and NMR

analyses were repeated. The residual amount of starting material in the final solution (86%; with respect to the initial spectrum) was calculated by the relative integral of Cp signals with respect to Me₂SO₂ as the internal standard. No change in the *cis/trans* ratio was observed.

4.3. X-ray Crystallography. Crystal data and collection details for [4]CF₃SO₃·0.5CH₃CN are reported in Table 1. Data were

Table 1. Crystal Data and Measurement Details for [4]CF₃SO₃·0.5CH₃CN

	[4]CF ₃ SO ₃ ·0.5CH ₃ CN
formula	C ₃₀ H _{35.5} F ₃ Fe ₂ N _{4.5} O ₅ PS
FW	770.86
T, K	100(2)
λ, Å	0.71073
crystal system	monoclinic
space group	P2 ₁ /c
a, Å	10.4934(6)
b, Å	24.3729(14)
c, Å	12.9622(7)
β, deg	111.780(2)
cell volume, Å ³	3078.5(3)
Z	4
D _c , g·cm ⁻³	1.663
μ, mm ⁻¹	1.130
F(000)	1588
crystal size, mm	0.21 × 0.18 × 0.14
Θ limits, deg	1.671–26.999
reflections collected	45009
independent reflections	6652 [R _{int} = 0.0358]
data/restraints/parameters	6652/23/438
goodness of fit of F ²	1.247
R ₁ (I > 2σ(I))	0.0408
wR ₂ (all data)	0.0951
largest diff peak and hole, e Å ⁻³	1.336/−0.500

recorded on a Bruker APEX II diffractometer equipped with a PHOTON100 detector using Mo-Kα radiation. Data were corrected for Lorentz polarization and absorption effects (empirical absorption correction SADABS).⁴⁰ The structure was solved by direct methods and refined by full-matrix least-squares based on all data using F².⁴¹ Hydrogen atoms were fixed at calculated positions and refined by a riding model. All non-hydrogen atoms were refined with anisotropic displacement parameters.

4.4. Photolysis Studies. Photolysis experiments were conducted using a CCP-ICH2 photoreactor from Luzchem (<https://www.luzchem.com>) fitted with 16 deuterium lamps with emission wavelengths centered at 350 nm (fwhm ± 25 nm; E_v ~ 6 mW/cm²). A quartz fluorescence cuvette from Hellma (V = 3 mL; d = 1 cm) was used as the reaction vessel.

To determine how much light is absorbed through a photoreaction, ferrioxalate actinometry experiments were performed as described in the literature.^{5e,42} A photon flow (I_{abs}) of about 3.8 × 10⁻⁸ Einstein/s was determined. The reaction rate of a photoreaction is best described by eq 1. Conditional rate constants can be derived where pseudo-first-order kinetics is observed

$$-\frac{dc}{dt} = \phi \cdot \frac{I_{\text{abs}}}{V} = k \cdot c \quad (1)$$

where *c* represents concentration, *t* represents time, $\frac{I_{\text{abs}}}{V}$ represents the absorbed light flux density (photon flux per irradiated volume), *A* represents absorbance, and Φ represents quantum yield. The quantum yield can be directly derived when the photon flux is known. For IR studies, 4–5 mg of each sample was dissolved in 3 mL of H₂O (K[2]), 0.8% v/v DMSO in water ([1]CF₃SO₃, [3]NO₃), or

MeCN ([4]CF₃SO₃, [5]CF₃SO₃) and irradiated for 5, 10, 30, and 60 min at 350 nm at 37 °C. Aliquots (700 μL) of each time point were lyophilized, and the IR (ATR) spectrum of the solid samples was recorded (1600–2300 cm⁻¹).

Myoglobin Assay. Lyophilized equine heart myoglobin (13 mg, Sigma-Aldrich) was dissolved in 8.5 mL of a 10 mM PBS buffer solution (pH 7.4). The solution was filtered to ensure optical clarity and degassed under nitrogen. A myoglobin solution (2.5 mL) was added to a sealed 3 mL fluorescence cuvette, and ca. 3 mg of sodium dithionite (8 mM) was then added. The UV spectrum of the deoxy-Mb solution was then recorded to determine the exact concentration (A₅₆₀ = 13800 L·mol⁻¹·cm⁻¹).⁴³ An aliquot of a stock solution of [3]NO₃ (3 mM, 14.2 μL) in 10 mM PBS buffer was then added to the reduced myoglobin solution, with final concentrations of 17 μM [3]NO₃ and 68 μM myoglobin (1:4 molar ratio). The cuvette was sealed with a plug to prevent the escape of CO or reoxidation of the myoglobin. Solutions were initially kept in the dark to study the stability of the complexes in the presence of sodium dithionite for 15 min and then exposed to UV light (350 nm, E_v = 6 mW/cm², 25 °C). The number of CO equivalents released per mole of diiron complex was calculated as reported.⁴⁴

4.5. Cell Experiments. Human A431 (skin epidermoid carcinoma) and HEK293 (human embryonic kidney) cell lines were purchased from CLS (Cell Lines Service GmbH, Eppelheim, Germany) and DSMZ Leibniz Institute (DSMZ—German Collection of Microorganisms and Cell Cultures). The cells were cultivated in Dulbecco's Modified Eagle Medium (DMEM) without the phenol red indicator and supplemented with heat inactivated 10% fetal bovine serum (FBS), penicillin, and streptomycin. All ingredients of cell medium were purchased from BIOCHROM or Thermo Fisher Scientific. The MTS assay cell experiments were performed in Cellstar transparent flat bottom 48-well plates. The cells were seeded with a density of 10 000 cells per well. Each well contained 200 μL of media. Cells were incubated for 24 h at 37 °C in a humidified atmosphere enriched with 5% CO₂. The selected diiron compound was added after 24 h of seeding. A freshly prepared 12.5 mM stock solution of the diiron compounds in 100% DMSO ([1]CF₃SO₃, [4]CF₃SO₃, and [5]CF₃SO₃) or in PBS (K[2] and [3]NO₃) was diluted with cell medium depending on the final concentration (10/20/40/60/80/100 μM for 1⁺, 2⁺, and 4⁺ and 12.5/25/50/75/100/125 μM for 3⁺ and 5⁺). The final concentration of DMSO in each well was 0.8% v/v. Two negative controls were used: either DMSO-containing cell medium (0.8% v/v) or just cell medium with final volumes of 200 μL per well. The outer wells were filled with phosphate buffer (PBS) to prevent the samples from evaporating. After 4 h from treatment with the respective complex, cells were irradiated at 350 nm for 10 min using the Luzchem photoreactor CCP-ICH2 at 37 °C. Fresh DMEM medium (100 μL) without the phenol red indicator was added to each well. The well plates were then stored in the incubator. Control cells were also irradiated, in order to compensate for the cell-killing effects of UV light.⁴⁵ Cell viability was determined using the commercially available Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay MTS kit. Twenty-four and 48 h after the irradiation, 60 μL of the MTS reagent was added to each well and left in the incubator for an additional 1–2 h. The formed formazan was detected at 492 nm using the TECAN microplate reader Sunrise. IC₅₀ values were obtained by the fitting four-parameter logistic nonlinear regression model, also known as the Hill equation using GraphPad Prism (version 9.3.0).

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.inorgchem.2c00504>.

IR, NMR, and UV–vis spectra of compounds in organic solvents, aqueous solution and upon UV irradiation. Cell viability experiments (PDF)

Accession Codes

CCDC 2151575 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

AUTHOR INFORMATION

Corresponding Author

Lorenzo Biancalana – Department of Chemistry and Industrial Chemistry, University of Pisa, 56124 Pisa, Italy; orcid.org/0000-0002-9276-0095; Email: lorenzo.biancalana@unipi.it

Authors

Manja Kubeil – Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, 01328 Dresden, Germany; orcid.org/0000-0001-8857-5922

Silvia Schoch – Department of Chemistry and Industrial Chemistry, University of Pisa, 56124 Pisa, Italy

Stefano Zacchini – Department of Industrial Chemistry “Toso Montanari”, University of Bologna, 40136 Bologna, Italy; orcid.org/0000-0003-0739-0518

Fabio Marchetti – Department of Chemistry and Industrial Chemistry, University of Pisa, 56124 Pisa, Italy; orcid.org/0000-0002-3683-8708

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acs.inorgchem.2c00504>

Author Contributions

Conceptualization, F.M., L.B.; methodology, L.B., M.K.; investigation, L.B., M.K., S.S., S.Z.; writing—original draft preparation, L.B.; writing—review and editing, L.B., M.K., S.Z., F.M. All authors have read and agreed to the published version of the manuscript.

Funding

L.B. and F.M. gratefully thank the University of Pisa (PRA_2020_39) for financial support. M.K. was supported by a Marie Curie International Outgoing Fellowship from European Union's Seventh Framework Programme for research, technological development, and demonstration under grant agreement no. 627113.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Utta Herzog for excellent technical assistance regarding cell culturing.

REFERENCES

- (1) Anthony, E. J.; Bolitho, E. M.; Bridgewater, H. E.; Carter, O. W. L.; Donnelly, J. M.; Imberti, C.; Lant, E. C.; Lermite, F.; Needham, R. J.; Palau, M.; Sadler, P. J.; Shi, H.; Wang, F.-X.; Zhang, W.-Y.; Zhang, Z. Metallo drugs are unique: opportunities and challenges of discovery and development. *Chem. Sci.* **2020**, *11*, 12888–12917.
- (2) Selected reviews on the topic: (a) Ling, K.; Men, F.; Wang, W.-C.; Zhou, Y.-Q.; Zhang, H.-W.; Ye, D.-W. Carbon Monoxide and Its Controlled Release: Therapeutic Application, Detection, and Development of Carbon Monoxide Releasing Molecules (CORMs). *J. Med. Chem.* **2018**, *61*, 2611–2635. (b) Romão, C. C.; Blättler, W. A.; Seixas, J. D.; Bernardes, G. J. L. Developing drug molecules for therapy with carbon monoxide. *Chem. Soc. Rev.* **2012**, *41*, 3571–3583.

- (c) Motterlini, R.; Otterbein, L. E. The therapeutic potential of carbon monoxide. *Nat. Rev. Drug Discovery* **2010**, *9*, 728–743.
- (d) Tien Vo, T. T.; Vo, Q. C.; Tuan, V. P.; Wee, Y.; Cheng, H.-C.; Lee, I.-T. The potentials of carbon monoxide-releasing molecules in cancer treatment: An outlook from ROS biology and medicine. *Redox Biol.* **2021**, *46*, 102124.

- (3) Selected review articles on the topic: (a) Chakraborty, I.; Carrington, S. J.; Mascharak, P. K. Design Strategies To Improve the Sensitivity of Photoactive Metal Carbonyl Complexes (photo-CORMs) to Visible Light and Their Potential as CO-Donors to Biological Targets. *Acc. Chem. Res.* **2014**, *47*, 2603–2611. (b) Wright, M. A.; Wright, J. A. PhotoCORMs: CO release moves into the visible. *Dalton Trans.* **2016**, *45*, 6801–6811. (c) Soboleva, T.; Berreau, L. M. Tracking CO Release in Cells via the Luminescence of Donor Molecules and/or their By-products. *Isr. J. Chem.* **2019**, *59*, 339–350. (d) Jiang, X.; Xiao, Z.; Zhong, W.; Liu, X. Brief survey of diiron and mononuclear carbonyl complexes and their potentials as CO-releasing molecules (CORMs). *Coord. Chem. Rev.* **2021**, *429*, 213634.

- (4) Selected references: (a) Atkin, A. J.; Fairlamb, I. J. S.; Ward, J. S.; Lynam, J. M. CO Release from Norbornadiene Iron(0) Tricarbonyl Complexes: Importance of Ligand Dissociation. *Organometallics* **2012**, *31*, 5894–5902. (b) Poh, H. T.; Ting Sim, B.; Sian Chwee, T.; Kee Leong, W.; Yip Fan, W. The Dithiolate-Bridged Diiron Hexacarbonyl Complex $\text{Na}_2[(\mu\text{-SCH}_2\text{CH}_2\text{COO})\text{Fe}(\text{CO})_3]_2$ as a Water-Soluble PhotoCORM. *Organometallics* **2014**, *33*, 959–963. (c) Mede, R.; Traber, J.; Klein, M.; Görls, H.; Gessner, G.; Hoffmann, P.; Schmitt, M.; Popp, J.; Heinemann, S. H.; Neugebauer, U.; Westerhausen, M. Synthesis and solution stability of water-soluble $\kappa^2\text{N}_2\kappa^1\text{O}$ -bis(3,5-dimethylpyrazolyl)ethanol manganese(I) tricarbonyl bromide (CORM-ONN1). *Dalton Trans.* **2017**, *46*, 1684–1693. (d) G, U. R.; Axthelm, J.; Hoffmann, P.; Taye, N.; Glaser, S.; Görls, H.; Hopkins, S. L.; Plass, W.; Neugebauer, U.; Bonnet, S.; Schiller, A. Co-Registered Molecular Logic Gate with a CO-Releasing Molecule Triggered by Light and Peroxide. *J. Am. Chem. Soc.* **2017**, *139*, 4991–4994. (e) Gessner, G.; Rühl, P.; Westerhausen, M.; Hoshi, T.; Heinemann, S. H. Fe^{2+} -Mediated Activation of BKCa Channels by Rapid Photolysis of CORM-S1 Releasing CO and Fe^{2+} . *ACS Chem. Biol.* **2020**, *15*, 2098–2106.

- (5) (a) Niesel, J.; Pinto, A.; Peindy N'Dongo, H. W.; Merz, K.; Ott, I.; Gust, R.; Schatzschneider, U. Photoinduced CO release, cellular uptake and cytotoxicity of a tris(pyrazolyl)methane (tpm) manganese tricarbonyl complex. *Chem. Commun.* **2008**, 1798–1800. (b) Chakraborty, I.; Carrington, S. J.; Hauser, J.; Oliver, S. R. J.; Mascharak, P. K. Rapid Eradication of Human Breast Cancer Cells through Trackable Light-Triggered CO Delivery by Mesoporous Silica Nanoparticles Packed with a Designed photoCORM. *Chem. Mater.* **2015**, *27*, 8387–8397. (c) Carrington, S. J.; Chakraborty, I.; Bernard, J. M. L.; Mascharak, P. K. A Theranostic Two-Tone Luminescent PhotoCORM Derived from Re(I) and (2-Pyridyl)-benzothiazole: Trackable CO Delivery to Malignant Cells. *Inorg. Chem.* **2016**, *55*, 7852–7858. (d) Kumar, C. A.; Nagarajaprakash, R.; Victoria, W.; Veena, V.; Sakthivel, N.; Manimaran, B. Synthesis, characterisation and cytotoxicity studies of Manganese(I) and Rhenium(I) based metal-lacrown ethers. *Inorg. Chem. Commun.* **2016**, *64*, 39–44. (e) Geri, S.; Krunclova, T.; Janouskova, O.; Panek, J.; Hruby, M.; Hernandez-Valdés, D.; Probst, B.; Alberto, R. A.; Mamat, C.; Kubeil, M.; Stephan, H. Light-Activated Carbon Monoxide Prodrugs Based on Bipyridyl Dicarbonyl Ruthenium(II) Complexes. *Chem.—Eur. J.* **2020**, *26*, 10992–11006.

- (6) Tinajero-Trejo, M.; Rana, N.; Nagel, C.; Jesse, H. E.; Smith, T. W.; Wareham, L. K.; Hippler, M.; Schatzschneider, U.; Poole, R. K. Antimicrobial Activity of the Manganese Photoactivated Carbon Monoxide-Releasing Molecule $[\text{Mn}(\text{CO})_3(\text{tpa-j3N})]^+$ Against a Pathogenic *Escherichia coli* that Causes Urinary Infections, Antioxid. *Redox Signal.* **2016**, *24*, 765–780.

- (7) (a) Carrington, S. J.; Chakraborty, I.; Mascharak, P. K. Rapid CO release from a Mn(I) carbonyl complex derived from azopyridine upon exposure to visible light and its phototoxicity toward malignant cells. *Chem. Commun.* **2013**, *49*, 11254–11256. (b) Carrington, S. J.;

- Chakraborty, I.; Bernard, J. M. L.; Mascharak, P. K. Synthesis and Characterization of a "Turn-On" photoCORM for Trackable CO Delivery to Biological Targets. *ACS Med. Chem. Lett.* **2014**, *5*, 1324–1328. (c) Chakraborty, I.; Carrington, S. J.; Roseman, G.; Mascharak, P. K. Synthesis, Structures, and CO Release Capacity of a Family of WaterSoluble PhotoCORMs: Assessment of the Biocompatibility and Their Phototoxicity toward Human Breast Cancer Cells. *Inorg. Chem.* **2017**, *56*, 1534–1545. (d) Jimenez, J.; Chakraborty, I.; Dominguez, A.; Martinez-Gonzalez, J.; Chamil Sameera, W. M.; Mascharak, P. K. A Luminescent Manganese PhotoCORM for CO Delivery to Cellular Targets under the Control of Visible Light. *Inorg. Chem.* **2018**, *57*, 1766–1773. (e) Kawahara, B.; Gao, L.; Cohn, W.; Whitelegge, J. P.; Sen, S.; Janzenc, C.; Mascharak, P. K. Diminished viability of human ovarian cancer cells by antigen-specific delivery of carbon monoxide with a family of photoactivatable antibodyphotoCORM conjugates. *Chem. Sci.* **2020**, *11*, 467–473.
- (8) Southam, H. M.; Smith, T. W.; Lyon, R. L.; Liao, C.; Trevitt, C. R.; Middlemiss, L. A.; Cox, F. L.; Chapman, J. A.; El-Khamisy, S. F.; Hippler, M.; Williamson, M. P.; Henderson, P. J. F.; Poole, R. K. A thiol-reactive Ru(II) ion, not CO release, underlies the potent antimicrobial and cytotoxic properties of CO-releasing molecule-3. *Redox Biol.* **2018**, *18*, 114–123.
- (9) (a) Sanchez, M.; Sabio, L.; Gaalvez, N.; Capdevila, M.; Dominguez-Vera, J. M. Iron Chemistry at the Service of Life. *IUBMB Life* **2017**, *69*, 382–388. (b) Patra, M.; Gasser, G. The medicinal chemistry of ferrocene and its derivatives. *Nat. Chem. Rev.* **2017**, *1*, 0066. (c) Valente, A.; Morais, T. S.; Teixeira, R. G.; Matos, C. P.; Tomaz, A. L.; Garcia, M. H. Ruthenium and iron metallodrugs: new inorganic and organometallic complexes as prospective anticancer agents. *Synthetic Inorganic Chemistry*; Elsevier: 2021; Chapter 6, p 223, DOI: 10.1016/B978-0-12-818429-5.00010-7.
- (10) (a) Jaouen, G.; Vessières, A.; Top, S. Ferrocifen type anti cancer drugs. *Chem. Soc. Rev.* **2015**, *44*, 8802. (b) Patra, M.; Gasser, G. The medicinal chemistry of ferrocene and its derivatives. *Nat. Rev. Chem.* **2017**, *1*, 0066. (c) McCarthy, J. S.; Rückle, T.; Djeriou, E.; Cantalloube, C.; Ter-Minassian, D.; Baker, M.; O'Rourke, P.; Griffin, P.; Marquart, L.; van Huijsduijnen, R. H.; Möhrle, J. J. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. *Malar. J.* **2016**, *15*, 469. (d) Kondratskyi, A.; Kondratska, K.; Abele, F. V.; Gordienko, D.; Dubois, C.; Toillon, R.-A.; Slomianny, C.; Lemièrre, S.; Delcourt, P.; Dewailly, E.; Skryma, R.; Biot, C.; Prevarskaya, N. Ferroquine, the next generation antimalarial drug, has antitumor activity. *Sci. Rep.* **2017**, *7*, 15896.
- (11) (a) Wagner, R. E.; Jacobson, R. A.; Angelici, R. J.; Quick, M. H. Synthesis of thiocarbonyl-bridged(η^5 -C₅H₅)₂Fe₂(CO)₃(CS) and crystal structure of an s-alkylated derivative. *J. Organomet. Chem.* **1978**, *148*, C35–C39. (b) Quick, M. H.; Angelici, R. J. Substitution and S-alkylation reactions of thiocarbonyl-bridged Cp₂Fe₂(CO)₃CS. *Inorg. Chem.* **1981**, *20*, 1123–1130. (c) Schroeder, N. C.; Funchess, R.; Jacobson, R. A.; Angelici, R. J. Reactions of Cp₂Fe₂(CO)₂(μ -CO)(μ -CSR)+ Bridging-Carbyne Complexes with Nucleophiles. *Organometallics* **1989**, *8*, 521–529. (d) English, R. B.; Haines, R. J.; Nolte, C. R. Reactions of Metal Carbonyl Derivatives. Synthesis and Redox Properties of Some Binuclear Derivatives of Iron Bridged by both Carbonyl and Alkylthio-groups. *J. Chem. Soc., Dalton Trans.* **1975**, 1030–1033.
- (12) Biancalana, L.; Ciancaleoni, G.; Zacchini, S.; Pampaloni, G.; Marchetti, F. Carbonyl-isocyanide mono-substitution in [Fe₂Cp₂(CO)₄]: A re-visitation. *Inorg. Chim. Acta* **2021**, *517*, 120181.
- (13) Agonigi, G.; Bortoluzzi, M.; Marchetti, F.; Pampaloni, G.; Zacchini, S.; Zanotti, V. Regioselective Nucleophilic Additions to Diiron Carbonyl Complexes Containing a Bridging Aminocarbyne Ligand: A Synthetic, Crystallographic and DFT Study. *Eur. J. Inorg. Chem.* **2018**, *2018*, 960–971.
- (14) Albano, V. G.; Busetto, L.; Monari, M.; Zanotti, V. Reactions of acetonitrile di-iron μ -aminocarbyne complexes; synthesis and structure of [Fe₂(μ -CNMe₂)(μ -H)(CO)₂(Cp)₂]. *J. Organomet. Chem.* **2000**, *606*, 163–168.
- (15) (a) Busetto, L.; Marchetti, F.; Zacchini, S.; Zanotti, V.; Zoli, E. Diiron-aminocarbyne complexes with amine or imine ligands: C–N coupling between imine and aminocarbyne ligands promoted by tolylacylidyne addition. *J. Organomet. Chem.* **2005**, *690*, 348–357. (b) Albano, V. G.; Busetto, L.; Marchetti, F.; Monari, M.; Zacchini, S.; Zanotti, V. Synthesis and Characterization of New Diiron and Diruthenium μ -Aminocarbyne Complexes Containing Terminal S-, P- and C-Ligands. *Z. Naturforsch.* **2007**, *62b*, 427–438. (c) Marchetti, F.; Zacchini, S.; Zanotti, V. Coupling of Isocyanide and μ -Aminocarbyne Ligands in Diiron Complexes Promoted by Hydride Addition. *Organometallics* **2014**, *33*, 3990–3997.
- (16) Albano, V. G.; Busetto, L.; Marchetti, F.; Monari, M.; Zacchini, S.; Zanotti, V. Diiron μ -Vinyliminium Complexes from Acetylene Insertion into a Metal-Aminocarbyne Bond. *Organometallics* **2003**, *22*, 1326–1331.
- (17) (a) Agonigi, G.; Biancalana, L.; Lupo, M. G.; Montopoli, M.; Ferri, N.; Zacchini, S.; Binacchi, F.; Biver, T.; Campanella, B.; Pampaloni, G.; Zanotti, V.; Marchetti, F. Exploring the Anticancer Potential of Diiron Bis-cyclopentadienyl Complexes with Bridging Hydrocarbyl Ligands: Behavior in Aqueous Media and In Vitro Cytotoxicity. *Organometallics* **2020**, *39*, 645–657. (b) Biancalana, L.; De Franco, M.; Ciancaleoni, G.; Zacchini, S.; Pampaloni, G.; Gandin, V.; Marchetti, F. Easily Available and Amphiphilic Diiron Cyclopentadienyl Complexes Exhibit In Vitro Anticancer Activity in 2D and 3D Human Cancer Cells via Redox Modulation Triggered by CO Release. *Chem.—Eur. J.* **2021**, *27*, 10169–10185.
- (18) (a) Rocco, D.; Batchelor, L. K.; Agonigi, G.; Braccini, S.; Chiellini, F.; Schoch, S.; Biver, T.; Funaioli, T.; Zacchini, S.; Biancalana, L.; Ruggeri, M.; Pampaloni, G.; Dyson, P. J.; Marchetti, F. Anticancer Potential of Diiron Vinyliminium Complexes. *Chem.—Eur. J.* **2019**, *25*, 14801–14816. (b) Braccini, S.; Rizzi, G.; Biancalana, L.; Pratesi, A.; Zacchini, S.; Pampaloni, G.; Chiellini, F.; Marchetti, F. Anticancer Diiron Vinyliminium Complexes A Structure-Activity Relationship Study. *Pharmaceutics* **2021**, *13*, 1158. (c) Rocco, D.; Busto, N.; Pérez-Arnaiz, C.; Biancalana, L.; Zacchini, S.; Pampaloni, G.; Garcia, B.; Marchetti, F. Antiproliferative and bactericidal activity of diiron and monoiron cyclopentadienyl carbonyl complexes comprising a vinyl-aminoalkylidene unit. *Appl. Organomet. Chem.* **2020**, *34*, No. e5923.
- (19) Schrölkamp, S.; Völkl, A.; Lügger, T.; Hahn, F. E.; Beck, W.; Fehlhammer, W. P. Palladium-, Platin- und Eisenkomplexe mit Isocyanacetat: Ringschluß, säureinduzierte Ringöffnung, Diprotonierung. *Z. Anorg. Allg. Chem.* **2008**, *634*, 2940–2947.
- (20) Biancalana, L.; Batchelor, L. K.; Funaioli, T.; Zacchini, S.; Bortoluzzi, M.; Pampaloni, G.; Dyson, P. J.; Marchetti, F. α -Diimines as Versatile, Derivatizable Ligands in Ruthenium(II) p-Cymene Anticancer Complexes. *Inorg. Chem.* **2018**, *57*, 6669–6685.
- (21) (a) Phillips, A. D.; Gonsalvi, L.; Romerosa, A.; Vizza, F.; Peruzzini, M. Coordination chemistry of 1,3,5-triaza-7-phosphaadamantane (PTA) Transition metal complexes and related catalytic, medicinal and photoluminescent applications. *Coord. Chem. Rev.* **2004**, *248*, 955–993. (b) Murray, B. S.; Babak, M. V.; Hartinger, C. G.; Dyson, P. J. The development of RAPTA compounds for the treatment of tumors. *Coord. Chem. Rev.* **2016**, *306*, 86–114.
- (22) (a) Agarwal, T.; Kaur-Ghumaan, S. Mono- and dinuclear mimics of the [FeFe] hydrogenase enzyme featuring bis-(monothiolato) and 1,3,5-triaza-7-phosphaadamantane ligands. *Inorg. Chim. Acta* **2020**, *504*, 119442. (b) Singleton, M. L.; Crouthers, D. J.; Duttweiler, R. P.; Reibenspies, J. H.; Darensbourg, M. Y. Sulfonated diiron complexes as water-soluble models of the [FeFe]-hydrogenase enzyme active site. *Inorg. Chem.* **2011**, *50*, 5015–5026. (c) Vannucci, A. K.; Wang, S.; Nichol, G. S.; Lichtenberger, D. L.; Evans, D. H.; Glass, R. S. Electronic and geometric effects of phosphatrimazaadamantane ligands on the catalytic activity of an [FeFe] hydrogenase inspired complex. *Dalton Trans.* **2010**, *39*, 3050–3056. (d) Wang, Z.; Liu, J.; He, C.; Jiang, S.; Akemark, B.; Sun, L. Diiron azadithiolates with hydrophilic phosphatrimazaadamantane ligand as iron-only hydrogenase active site models: Synthesis, structure, and electrochemical study. *Inorg. Chim. Acta* **2007**, *360*,

- 2411–2419. (e) Na, Y.; Wang, M.; Jin, K.; Zhang, R.; Sun, L. An approach to water-soluble hydrogenase active site models: Synthesis and electrochemistry of diiron dithiolate complexes with 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane ligand(s). *J. Organomet. Chem.* **2006**, 691, 5045–5051. (f) Mejia-Rodriguez, R.; Chong, D.; Reibenspies, J. H.; Soriaga, M. P.; Darensbourg, M. Y. The Hydrophilic Phosphatrimazaadamantane Ligand in the Development of H₂ Production Electrocatalysts: Iron Hydrogenase Model Complexes. *J. Am. Chem. Soc.* **2004**, 126, 12004–12014.
- (23) (a) Farrugia, L. J. Dynamics and fluxionality in metal carbonyl clusters: some old and new problems. *J. Chem. Soc., Dalton Trans.* **1997**, 1783–1792. (b) Adams, R. D.; Cotton, F. A. Low-valent metal isocyanide complexes. V. Structure and dynamical stereochemistry of bis(pentahaptocyclopentadienyl)tricarbonyl(tert-butyl isocyanide)-diiron(Fe-Fe)(b5-C5H5)2Fe2(CO)3[CNC(CH3)3]. *Inorg. Chem.* **1974**, 13, 257–262.
- (24) Cox, G.; Dowling, C.; Manning, A. R.; McArdle, P.; Cunningham, D. A reinvestigation of the reaction of [Fe2(η -C5H5)2(CO)4-n(CNR)n] (n = 1 or 2) with strong alkylating agents. *J. Organomet. Chem.* **1992**, 438, 143–158.
- (25) (a) Busetto, L.; Marchetti, F.; Zacchini, S.; Zanotti, V. Diiron and diruthenium aminocarbyne complexes containing pseudohalides: stereochemistry and reactivity. *Inorg. Chim. Acta* **2005**, 358, 1204–1216. (b) Busetto, L.; Marchetti, F.; Zacchini, S.; Zanotti, V. Synthesis and reactivity with amines of new diiron alkynyl methoxy carbene complexes. *Inorg. Chim. Acta* **2005**, 358, 1469–1484. (c) Busetto, L.; Marchetti, F.; Zacchini, S.; Zanotti, V. Deprotonation of μ -Vinyliminium Ligands in Diiron Complexes: A Route for the Synthesis of Mono- and Polynuclear Species Containing Novel Multidentate Ligands. *Organometallics* **2005**, 24, 2297–2306. (d) Busetto, L.; Marchetti, F.; Zacchini, S.; Zanotti, V. Formation of C-C Bonds in Diiron Complexes by Addition of Carbanions to Alkynyl(methoxy)carbene Ligands. *Eur. J. Inorg. Chem.* **2005**, 2005, 3250–3260. (e) Busetto, L.; Marchetti, F.; Zacchini, S.; Zanotti, V. Addition of protic nucleophiles to alkynyl methoxy carbene ligands in diiron complexes. *Inorg. Chim. Acta* **2006**, 359, 3345–3352. (f) Marchetti, F.; Zacchini, S.; Zanotti, V. Coupling of Isocyanide and μ -Aminocarbyne Ligands in Diiron Complexes Promoted by Hydride Addition. *Organometallics* **2014**, 33, 3990–3997.
- (26) Dasari, S.; Tchounwou, P. B. Cisplatin in cancer therapy: Molecular mechanisms of action. *Eur. J. Pharmacol.* **2014**, 740, 364–378.
- (27) Jiang, X.; Chen, L.; Wang, X.; Long, L.; Xiao, Z.; Liu, X. Photoinduced Carbon Monoxide Release from Half-Sandwich Iron(II) Carbonyl Complexes by Visible Irradiation: Kinetic Analysis and Mechanistic Investigation. *Chem.—Eur. J.* **2015**, 21, 13065–13072.
- (28) Motterlini, R.; Clark, J. E.; Foresti, R.; Sarathchandra, P.; Mann, B. E.; Green, C. J. Carbon Monoxide-Releasing Molecules - Characterization of Biochemical and Vascular Activities. *Circ. Res.* **2002**, 90, e17–e24.
- (29) The influence of the counteranion (CF₃SO₃[−] vs NO₃[−]) on the position of the carbonyl infrared bands should be considered (see Figure S3).
- (30) (a) Scapens, D.; Adams, H.; Johnson, T. R.; Mann, B. E.; Sawle, P.; Aqil, R.; Perriore, T.; Motterlini, R. [(η -C5H4R)Fe(CO)2X], X = Cl, Br, I, NO₃, CO₂Me and [(η -C5H4R)Fe(CO)3]⁺, R = (CH₂)_nCO₂Me (n = 0–2), and CO₂CH₂CH₂OH: a new group of CO-releasing molecules. *Dalton Trans.* **2007**, 4962–4973. (b) Hewison, L.; Crook, S. H.; Johnson, S. H.; Mann, B. E.; Adams, H.; Plant, S. E.; Sawle, P.; Motterlini, R. Iron indenyl carbonyl compounds: CO-releasing molecules. *Dalton Trans.* **2010**, 39, 8967–8975.
- (31) The absence of photocytotoxic effects does not imply the absence of cytotoxicity: note that [1]CF₃SO₃ is cytotoxic even without UV-light exposure.
- (32) Biancalana, L.; Marchetti, F. Aminocarbyne ligands in organometallic chemistry. *Coord. Chem. Rev.* **2021**, 449, 214203.
- (33) (a) Dombek, B. D.; Choi, M.-G.; Angelici, R. J.; Butler, I. S.; Cozak, D. Dicarboxyl(η 5-Cyclopentadienyl)-(Thiocarbonyl)Iron(1+) Trifluoromethane-Sulfonate(1-) and Dicarboxyl(η 5-Cyclopentadienyl)[(Methylthio)Thiocarbonyl]Iron. *Inorganic Syntheses*; 1990; Vol. 28, p 186. (b) Beckman, D. E.; Jacobson, R. A. Crystal and molecular structure of (C5H5)2Fe2(CO)3CS, a carbonyl, thiocarbonyl-bridged diiron complex. *J. Organomet. Chem.* **1979**, 179, 187–196.
- (34) (a) Harris, R. K.; Becker, E. D.; Cabral De Menezes, S. M.; Goodfellow, R.; Granger, P. NMR nomenclature. Nuclear spin properties and conventions for chemical shifts (IUPAC Recommendations 2001). *Pure Appl. Chem.* **2001**, 73, 1795–1818. (b) Fulmer, G. R.; Miller, A. J. M.; Sherden, N. H.; Gottlieb, H. E.; Nudelman, A.; Stoltz, B. M.; Bercaw, J. E.; Goldberg, K. I. NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist. *Organometallics* **2010**, 29, 2176–2179.
- (35) Menges, F. *Spectragryph - optical spectroscopy software*, Version 1.2.16d, @ 2016-2020. <http://www.ffmpeg2.de/spectragryph> (accessed 2022-05-05).
- (36) Busetto, L.; Calucci, L.; Zanotti, V.; Albano, V. G.; Braga, D. Synthesis, reactions, and X-ray structures of the functionalized isocyanide complexes [Fe2{ μ -CNC(O)SR}{ μ -CO}(CO)2(cp)2] (cp = η -C5H5, R = Me or Et) and of their carbyne and carbene derivatives. *J. Chem. Soc., Dalton Trans.* **1990**, 243–250.
- (37) Galan, B. R.; Kalbarczyk, K. P.; Szczepankiewicz, S.; Keister, J. B.; Diver, S. T. A Rapid and Simple Cleanup Procedure for Metathesis Reactions. *Org. Lett.* **2007**, 9, 1203–1206.
- (38) Bonne, D.; Dekhane, M.; Zhu, J. Ammonium Chloride Promoted Ugi Four-Component, Five-Center Reaction of α -Substituted α -Isocyano Acetic Acid: A Strong Solvent Effect. *Org. Lett.* **2004**, 6, 4771–4774.
- (39) Willis, S.; Manning, A. R.; Stephens, F. S. Reactions of [Fe2(η -dienyl)2(CO)4-n(CNR)n] Complexes (dienyl = C5H5 C5H4Me or C9H7; R = alkyl or benzyl; n = 1 or 2) with Alkyl Halides and Other Alkylating Agents. The Crystal Structure of cis-[Fe2(η -C5H4Me)2(CO)2(CNMe2)]. *J. Chem. Soc., Dalton Trans.* **1980**, 186–191.
- (40) Sheldrick, G. M. *SADABS-2008/1 - Bruker AXS Area Detector Scaling and Absorption Correction*; Bruker AXS: Madison, Wisconsin, USA, 2008.
- (41) Sheldrick, G. M. Crystal structure refinement with SHELXL. *Acta Cryst. C* **2015**, 71, 3.
- (42) (a) Bowman, W. D.; Demas, J. N. Ferrioxalate actinometry. A warning on its correct use. *J. Phys. Chem.* **1976**, 80, 2434–2435. (b) Hatchard, C. G.; Parker, C. A. A new sensitive chemical actinometer - II. Potassium ferrioxalate as a standard chemical actinometer. *Proc. R. Soc. London A* **1956**, 235, 518–536.
- (43) Antonini, E.; Brunori, M. Hemoglobin and myoglobin in their reactions with ligands. In *Frontiers of Biology*; Neuberger, A., Tatum, E. L., Eds.; North-Holland: Amsterdam, 1971; Vol. 21.
- (44) Bischof, C.; Joshi, T.; Dimri, A.; Spiccia, L.; Schatzschneider, U. Synthesis, Spectroscopic Properties, and Photoinduced CO-Release Studies of Functionalized Ruthenium(II) Polypyridyl Complexes: Versatile Building Blocks for Development of CORM-Peptide Nucleic Acid Bioconjugates. *Inorg. Chem.* **2013**, 52 (16), 9297–9308.
- (45) Bonnet, S. Shifting the Light Activation of Metallo-drugs to the Red and Near-Infrared Region in Anticancer Phototherapy. *Comments Inorg. Chem.* **2015**, 35, 179–213.